In a turbulent market environment, Moderna Inc (BMV:MRNA). shares have touched a 52-week low, sinking to $30.7, with concerning financial metrics showing negative EBITDA of $2.36 billion and gross ...

Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Pharmaceutical giant Moderna, Inc. (NASDAQ:MRNA) saw its share prices drop by 9.39 percent on Wednesday to close at $40.72 ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BRSE:0QF) from Buy to Neutral. There are 1,448 funds or institutions reporting positions in Moderna.

Goldman Sachs would consider acquisitions in asset and wealth management, but would be highly selective about any deal, CEO ...